$A multicentre NCRI phase II study of hypofractionated conformal radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer$

A multicentre NCRI phase II study of hypofractionated conformal radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer

Bibliographic Details
Main Authors:	Choudhury, A, Swindell, R, Logue, J, Kiltie, A, Clarke, N, Cowan, R
Format:	Conference item
Published:	2010

Similar Items

Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer.
by: Choudhury, A, et al.
Published: (2011)

Gemcitabine as a Chemoradiosensitiser in Bladder Cancer
by: Kerr, M, et al.
Published: (2012)

Utility of bladder-sparing therapy vs radical cystectomy for muscle-invasive bladder cancer
by: Efstathiou, J, et al.
Published: (2018)

Predictive Biomarkers for Gemcitabine as a Chemoradiosensitizer in Bladder Cancer
by: Kerr, M, et al.
Published: (2012)

Treatment of Breast and Prostate Cancer by Hypofractionated Radiotherapy: Potential Risks and Benefits
by: Ray, K, et al.
Published: (2015)

Treatment of breast and prostate cancer by hypofractionated radiotherapy: potential risks and benefits
by: Ray, KJ, et al.
Published: (2015)

MRE11 variants as predictive markers of radiotherapy response in muscle invasive bladder cancer
by: Teo, M, et al.
Published: (2012)

Ultrasound mediated gemcitabine delivery reduces the normal tissue toxicity of chemoradiation therapy in a muscle-invasive bladder cancer model
by: Ruan, J-L, et al.
Published: (2021)

High MRE11 expression in muscle invasive bladder cancer is predictive of improved cause-specific survival following radical radiotherapy compared to surgery
by: Teo, T, et al.
Published: (2010)

MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer.
by: Choudhury, A, et al.
Published: (2010)

Improved Outcomes With Dose Escalated Hypofractionated Radiotherapy for Prostate Cancer
by: Mackenzie, J, et al.
Published: (2011)

Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer
by: Teo, M, et al.
Published: (2014)

Comparison of treatment outcome for radical surgery versus radical radiotherapy for invasive bladder cancer treated in a UK specialist treatment centre
by: Kotwal, S, et al.
Published: (2007)

Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center.
by: Kotwal, S, et al.
Published: (2008)

Predictive biomarkers in muscle-invasive bladder cancer
by: Walker, A
Published: (2017)

Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future
by: Hermans, TJN, et al.
Published: (2017)

Contemporary patterns of multidisciplinary care in patients with muscle-invasive bladder cancer
by: Harshman, LC, et al.
Published: (2017)

Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network
by: Zuiverloon, TCM, et al.
Published: (2018)

Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy.
by: Higgins, G, et al.
Published: (2006)

Review of hypofractionated small volume radiotherapy for early-stage non-small cell lung cancer.
by: Brock, J, et al.
Published: (2008)

Mouse models of muscle-invasive bladder cancer: Key considerations for clinical translation based on molecular subtypes
by: Ruan, J, et al.
Published: (2018)

Conventional radiotherapy or hypofractionation? A study of molecular changes resulting from different radiation fractionation schemes.
by: Hamilton, J, et al.
Published: (2009)

THE HYPOXIC REGULATION OF FGFR3 IN NON MUSCLE INVASIVE BLADDER CANCER
by: Blick, C, et al.
Published: (2011)

Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center: In regard to Kotwal et al. - In reply to Dr. Rosario et al.
by: Kiltie, A, et al.
Published: (2008)

High-throughput DNA sequencing identifies novel CtIP (RBBP8) variants in muscle-invasive bladder cancer patients
by: Jevons, S, et al.
Published: (2015)

MRE11A isoform expression associated with outcome following radiotherapy in muscle-invasive bladder cancer does not alter cell survival and DNA double-strand break repair following ionising radiation
by: Walker, AK, et al.
Published: (2019)

Evaluation of loading strategies to improve tumor uptake of gemcitabine in a murine orthotopic bladder cancer model using ultrasound and microbubbles
by: Ruan, J-L, et al.
Published: (2021)

The management of non-muscle-invasive bladder cancer: A comparison of European and UK guidelines
by: Leiblich, A, et al.
Published: (2018)

MRE11 as a predictive biomarker of outcome following radiotherapy in bladder cancer
by: Walker, AK, et al.
Published: (2019)

Papillary and muscle invasive bladder tumors with distinct genomic stability profiles have different DNA repair fidelity and KU DNA-binding activities.
by: Bentley, J, et al.
Published: (2009)

High levels of patient satisfaction in joint uro-oncology clinics to assist patient choice in early prostate cancer and muscle-invasive bladder cancer
by: Kiltie, A, et al.
Published: (2018)

High levels of patient satisfaction in joint uro-oncology clinics to assist patient choice in early prostate cancer and muscle-invasive bladder cancer
by: Kiltie, A, et al.
Published: (2018)

APE1 and XRCC1 protein expression levels predict cancer-specific survival following radical radiotherapy in bladder cancer.
by: Sak, S, et al.
Published: (2005)

The clinical implications of gemcitabine radiosensitization.
by: Doyle, T, et al.
Published: (2001)

Numerical Study of Effects of Bladder Filling on Prostate Positioning In Radiotherapy
by: Krywonos, J, et al.
Published: (2009)

Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer
by: Ottley, EC, et al.
Published: (2020)

Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer: Interventional procedures guidance [IPG628]
by: National Institute for Health and Care Excellence, CA, et al.
Published: (2018)

Electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer: Interventional procedures guidance [IPG638]
by: National Institute for Health and Care Excellence, CA, et al.
Published: (2019)

PemBla: a Phase 1 study of intravesical pembrolizumab in recurrent non-muscle-invasive bladder cancer
by: Woodcock, VK, et al.
Published: (2023)

Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion.
by: Fujiyama, C, et al.
Published: (2001)